Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| AIDS Dementia Complex | 19 | 2025 | 116 | 3.490 |
Why?
|
| HIV Infections | 16 | 2025 | 2586 | 1.580 |
Why?
|
| Cognition Disorders | 9 | 2017 | 243 | 1.570 |
Why?
|
| HIV Seropositivity | 8 | 2018 | 196 | 1.070 |
Why?
|
| Receptor, Insulin | 2 | 2015 | 25 | 0.820 |
Why?
|
| HIV-1 | 10 | 2025 | 755 | 0.720 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2023 | 229 | 0.610 |
Why?
|
| Puerto Rico | 10 | 2020 | 1413 | 0.590 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 173 | 0.520 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 247 | 0.510 |
Why?
|
| Neuropsychological Tests | 8 | 2024 | 284 | 0.500 |
Why?
|
| Monocytes | 7 | 2025 | 277 | 0.480 |
Why?
|
| Access to Information | 1 | 2015 | 15 | 0.480 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 52 | 0.460 |
Why?
|
| Humans | 41 | 2025 | 43102 | 0.450 |
Why?
|
| Models, Biological | 1 | 2018 | 712 | 0.450 |
Why?
|
| Cell Movement | 1 | 2018 | 655 | 0.430 |
Why?
|
| Exercise | 1 | 2020 | 692 | 0.420 |
Why?
|
| Adult | 24 | 2025 | 13872 | 0.420 |
Why?
|
| Female | 30 | 2025 | 24698 | 0.400 |
Why?
|
| Macrophages | 5 | 2017 | 529 | 0.390 |
Why?
|
| Insulin Resistance | 1 | 2015 | 201 | 0.380 |
Why?
|
| Apolipoproteins | 1 | 2012 | 22 | 0.380 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 23 | 0.370 |
Why?
|
| DNA, Viral | 1 | 2013 | 311 | 0.360 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 160 | 0.350 |
Why?
|
| HIV | 2 | 2013 | 100 | 0.340 |
Why?
|
| Learning | 1 | 2012 | 161 | 0.340 |
Why?
|
| Middle Aged | 19 | 2025 | 12222 | 0.340 |
Why?
|
| Cognition | 3 | 2024 | 473 | 0.330 |
Why?
|
| Proteomics | 6 | 2017 | 378 | 0.330 |
Why?
|
| Basilar Artery | 1 | 2010 | 10 | 0.320 |
Why?
|
| Puerperal Disorders | 1 | 2010 | 16 | 0.320 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 61 | 0.320 |
Why?
|
| Education, Distance | 1 | 2010 | 46 | 0.310 |
Why?
|
| Thrombosis | 1 | 2010 | 81 | 0.300 |
Why?
|
| Dementia | 1 | 2010 | 160 | 0.290 |
Why?
|
| Research | 1 | 2007 | 181 | 0.240 |
Why?
|
| Protein Array Analysis | 2 | 2004 | 27 | 0.220 |
Why?
|
| Hippocampus | 2 | 2022 | 594 | 0.220 |
Why?
|
| Memory | 3 | 2012 | 174 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2024 | 1759 | 0.200 |
Why?
|
| Neurology | 2 | 2013 | 12 | 0.200 |
Why?
|
| Proteome | 2 | 2017 | 152 | 0.190 |
Why?
|
| Exosomes | 1 | 2025 | 126 | 0.190 |
Why?
|
| Flumazenil | 1 | 2000 | 1 | 0.170 |
Why?
|
| Midazolam | 1 | 2000 | 3 | 0.170 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 27 | 0.170 |
Why?
|
| Smoking | 1 | 2007 | 1024 | 0.170 |
Why?
|
| HIV Antibodies | 1 | 2020 | 24 | 0.160 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 17 | 0.160 |
Why?
|
| Glycopeptides | 1 | 2020 | 14 | 0.160 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 110 | 0.160 |
Why?
|
| Anthropometry | 1 | 2020 | 97 | 0.160 |
Why?
|
| Electroencephalography | 1 | 2000 | 139 | 0.150 |
Why?
|
| Cells, Cultured | 3 | 2018 | 1621 | 0.150 |
Why?
|
| Disease Progression | 3 | 2013 | 667 | 0.150 |
Why?
|
| Longitudinal Studies | 5 | 2013 | 1063 | 0.150 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 3156 | 0.140 |
Why?
|
| Quality of Life | 2 | 2013 | 616 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2015 | 2544 | 0.140 |
Why?
|
| Cerebrospinal Fluid | 2 | 2007 | 20 | 0.140 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2017 | 10 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 282 | 0.120 |
Why?
|
| Resilience, Psychological | 1 | 2017 | 106 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2018 | 972 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 1081 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2018 | 502 | 0.110 |
Why?
|
| Lymphocytes | 2 | 2013 | 124 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2017 | 341 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 28 | 0.110 |
Why?
|
| Viral Load | 4 | 2013 | 348 | 0.110 |
Why?
|
| Public Health | 1 | 2018 | 424 | 0.110 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 7 | 0.100 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2013 | 5 | 0.100 |
Why?
|
| Sampling Studies | 1 | 2013 | 64 | 0.100 |
Why?
|
| 14-3-3 Proteins | 1 | 2013 | 21 | 0.100 |
Why?
|
| Male | 9 | 2024 | 23409 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 458 | 0.100 |
Why?
|
| Epilepsy | 1 | 2013 | 59 | 0.100 |
Why?
|
| Cystatin B | 1 | 2013 | 11 | 0.100 |
Why?
|
| Fatigue | 1 | 2013 | 100 | 0.100 |
Why?
|
| Cathepsin B | 1 | 2013 | 35 | 0.100 |
Why?
|
| Gene Expression | 2 | 2013 | 701 | 0.100 |
Why?
|
| HIV Seronegativity | 2 | 2013 | 41 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 69 | 0.090 |
Why?
|
| Internet | 2 | 2012 | 236 | 0.090 |
Why?
|
| Reaction Time | 1 | 2012 | 157 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 223 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 77 | 0.090 |
Why?
|
| Alleles | 1 | 2012 | 352 | 0.090 |
Why?
|
| Psychometrics | 2 | 2017 | 358 | 0.090 |
Why?
|
| Prevalence | 2 | 2024 | 1612 | 0.080 |
Why?
|
| Pharmacology | 1 | 2010 | 6 | 0.080 |
Why?
|
| Thrombophilia | 1 | 2010 | 5 | 0.080 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 4 | 0.080 |
Why?
|
| Allergy and Immunology | 1 | 2010 | 14 | 0.080 |
Why?
|
| Neurosciences | 1 | 2010 | 34 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2007 | 201 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 734 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 719 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2012 | 986 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1285 | 0.070 |
Why?
|
| Aged | 4 | 2024 | 8214 | 0.070 |
Why?
|
| Mentors | 1 | 2010 | 145 | 0.070 |
Why?
|
| Antioxidants | 2 | 2010 | 443 | 0.070 |
Why?
|
| Language | 1 | 2010 | 185 | 0.070 |
Why?
|
| Health Status | 1 | 2012 | 442 | 0.070 |
Why?
|
| Catalase | 1 | 2008 | 110 | 0.070 |
Why?
|
| Glutathione Peroxidase | 1 | 2008 | 112 | 0.070 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 158 | 0.070 |
Why?
|
| Focus Groups | 1 | 2010 | 423 | 0.070 |
Why?
|
| Intelligence Tests | 1 | 2007 | 8 | 0.070 |
Why?
|
| ROC Curve | 1 | 2007 | 159 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2007 | 39 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 2853 | 0.070 |
Why?
|
| Hawaii | 1 | 2013 | 2011 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2006 | 7 | 0.060 |
Why?
|
| Women's Health | 1 | 2007 | 160 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 159 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2025 | 53 | 0.060 |
Why?
|
| Minority Groups | 1 | 2010 | 690 | 0.050 |
Why?
|
| Algorithms | 1 | 2007 | 509 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 704 | 0.050 |
Why?
|
| Cyclohexanes | 1 | 2023 | 30 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2007 | 1600 | 0.050 |
Why?
|
| Heroin | 1 | 2002 | 18 | 0.050 |
Why?
|
| Narcotics | 1 | 2002 | 29 | 0.050 |
Why?
|
| Triazoles | 1 | 2023 | 102 | 0.050 |
Why?
|
| California | 1 | 2024 | 548 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2017 | 575 | 0.050 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2002 | 83 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2017 | 883 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2003 | 269 | 0.040 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2020 | 20 | 0.040 |
Why?
|
| Depression | 1 | 2007 | 863 | 0.040 |
Why?
|
| Cricetulus | 1 | 2020 | 82 | 0.040 |
Why?
|
| CHO Cells | 1 | 2020 | 123 | 0.040 |
Why?
|
| Glycosylation | 1 | 2020 | 113 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 102 | 0.040 |
Why?
|
| Cricetinae | 1 | 2020 | 241 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 127 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 518 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 306 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2007 | 78 | 0.030 |
Why?
|
| Microwaves | 1 | 2017 | 29 | 0.030 |
Why?
|
| Insurance, Major Medical | 1 | 2017 | 5 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2024 | 719 | 0.030 |
Why?
|
| Magnetics | 1 | 2017 | 43 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2007 | 280 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 5080 | 0.030 |
Why?
|
| Adolescent | 2 | 2013 | 6081 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 182 | 0.030 |
Why?
|
| Calgranulin B | 1 | 2015 | 4 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 175 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 246 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 95 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 241 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1542 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 830 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1078 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2013 | 14 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 77 | 0.030 |
Why?
|
| Heterozygote | 1 | 2013 | 110 | 0.020 |
Why?
|
| Ceramides | 1 | 2013 | 44 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 485 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 201 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 37 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 440 | 0.020 |
Why?
|
| Cholesterol | 1 | 2013 | 232 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 411 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 2010 | 12 | 0.020 |
Why?
|
| Peroxiredoxins | 1 | 2010 | 11 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2010 | 68 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 57 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 64 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2010 | 41 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 536 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 162 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 166 | 0.020 |
Why?
|
| Complement C3 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 197 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 64 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 74 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 246 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 16992 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 182 | 0.020 |
Why?
|
| Glioma | 1 | 2007 | 96 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 532 | 0.020 |
Why?
|
| Neurons | 2 | 2003 | 1263 | 0.010 |
Why?
|
| Virus Replication | 1 | 2007 | 318 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1180 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 3994 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 780 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 5 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 2003 | 34 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 2002 | 36 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 55 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2002 | 54 | 0.010 |
Why?
|
| United States | 1 | 2013 | 5205 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 611 | 0.010 |
Why?
|
| Dopamine | 1 | 2002 | 275 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2676 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 638 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2003 | 486 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 1472 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 3735 | 0.010 |
Why?
|